Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Chimerix, Inc. - Common Stock
(NQ:
CMRX
)
8.460
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 12, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
73
Open
8.460
Bid (Size)
8.430 (30)
Ask (Size)
8.460 (25)
Prev. Close
8.460
Today's Range
8.460 - 8.460
52wk Range
0.7500 - 8.470
Shares Outstanding
86,249,744
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDFN, BLBX, CMRX, WBA on Behalf of Shareholders
March 12, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 2seventy bio, Inc. (Nasdaq - TSVT), Bridge Investment Group Holdings Inc. (NYSE - BRDG), Chimerix, Inc. (Nasdaq - CMRX), 180 Degree Capital Corp. (Nasdaq – TURN)
March 11, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
Performance
YTD
+149.56%
+149.56%
1 Month
+108.37%
+108.37%
3 Month
+183.89%
+183.89%
6 Month
+878.83%
+878.83%
1 Year
+616.95%
+616.95%
More News
Read More
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, CMRX, WBA on Behalf of Shareholders
March 11, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
This MongoDB Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday
March 06, 2025
Via
Benzinga
Demystifying Chimerix: Insights From 4 Analyst Reviews
March 05, 2025
Via
Benzinga
CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - CMRX
March 10, 2025
From
Kahn Swick & Foti, LLC
Via
Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VOXX, CMRX, WBA, ML on Behalf of Shareholders
March 08, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 07, 2025
From
Chimerix, Inc.
Via
GlobeNewswire
CMRX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Chimerix, Inc. is Fair to Shareholders
March 07, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
Unusual volume stocks are being observed in Thursday's session.
March 06, 2025
Via
Chartmill
Here are the top movers in Wednesday's session.
March 05, 2025
Via
Chartmill
These stocks are making the most noise in today's session.
March 05, 2025
Via
Chartmill
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX, IVAC, BRDG on Behalf of Shareholders
March 05, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
Which stocks are experiencing notable movement on Wednesday?
March 05, 2025
Via
Chartmill
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Chimerix, Inc. (Nasdaq - CMRX), Siyata Mobile Inc. (Nasdaq - SYTA), Bridge Investment Group Holdings Inc. (NYSE - BRDG), Intevac, Inc. (Nasdaq - IVAC)
March 05, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
Wednesday's session: gap up and gap down stocks
March 05, 2025
Via
Chartmill
These stocks that are showing activity before the opening bell on Wednesday.
March 05, 2025
Via
Chartmill
Jazz Pharma To Buy Chimerix For $935 Million, Strengthening Rare Cancer Pipeline
March 05, 2025
Via
Benzinga
CMRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Chimerix, Inc. Is Fair to Shareholders
March 05, 2025
From
Halper Sadeh LLC
Via
Business Wire
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
March 05, 2025
From
Chimerix, Inc.; Jazz Pharmaceuticals plc
Via
GlobeNewswire
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 18, 2025
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix Announces FDA Acceptance and Priority Review of New Drug Application for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma
February 18, 2025
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix to Present at JonesTrading Virtual Precision Medicine Symposium
January 29, 2025
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 24, 2025
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix to Speak Today at The White House Cancer Moonshot Forum
January 13, 2025
From
Chimerix, Inc.
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.